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Background: Inducible nitric oxide synthase (iNOS) induced by inﬂammatory cytokines and iNOS activity
in bronchial epithelial cells is a major determinant of fractional exhaled nitric oxide (FeNO) levels. The
aim of this study was to investigate the association of iNOS promoter gene polymorphisms and FeNO
levels in Japanese asthmatics before the introduction of asthma treatment.
Methods: Asthmatics were recruited from Fukushima Medical University Hospital. Genotyping of the
pentanucleotide repeat (CCTTT)n and seven previously detected single nucleotide polymorphisms (SNPs)
in the iNOS promoter lesion was performed. The relationships between the genotypes and FeNO levels
before the introduction of asthma treatment were compared.
Results: In 91 asthmatics, the number of microsatellite repeats ranged from 9 to 20 and showed a
bimodal distribution. According to this distribution, asthmatics were divided into two groups: genotypes
with at least one long allele with more than 14 repeats (L/s or L/L) and genotypes with both short alleles
with 14 or fewer repeats (s/s). No signiﬁcant differences were observed in each parameter between the
two groups. The mean FeNO level before treatment was signiﬁcantly higher in the L/s or L/L subjects than
in the s/s subjects. After treatment, the lowest FeNO level did not differ between the two groups. Three
SNPs detected in the Japanese subjects were not associated with FeNO levels.
Conclusions: The number of CCTTT repeats in the iNOS promoter region was associated with FeNO levels
in asthmatics before treatment, suggesting the importance of iNOS genotype in the clinical application of
FeNO for asthmatics.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Fractional exhaled nitric oxide (FeNO) is a useful diagnostic tool
for bronchial asthma.1e3 NO is produced by a wide variety of cells
and is generated through conversion of L-arginine to L-citrulline by
nitric oxide synthase.4 In addition, inducible nitric oxide synthase
(iNOS) is activated by inﬂammatory cytokines, and iNOS activity in
bronchial epithelial cells is a major determinant of FeNO level.5Medicine, School of Medicine,
ima 960-1295, Japan.
ety of Allergology.
rgology. Production and hosting by ElseThe inducible-NOS gene (NOS2A) is present on chromosome
17q11.2e12, which comprises 27 exons, with the transcription start
site in exon 2 and stop codon in exon 27.6 NOS2A is predominantly
transcriptionally regulated, therefore genetic variations within the
50 region may inﬂuence gene expression. The proximal NOS2A
promoter contains pentanucleotide microsatellites and single
nucleotide polymorphisms (SNPs). These polymorphisms play
important roles in several diseases. Pentanucleotide (CCTTT) poly-
morphisms in the promoter regions of NOS2A and other SNPs have
been investigated in various diseases including asthma, rheumatoid
arthritis, malaria, and inﬂammatory bowel diseases.7 Konno et al.
reported that a 14-repeat allele is inversely associated with atopy.8
Pascual et al. reported in their case control study that the number of
repeats could be associated with the inﬂammatory process of nasalvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
S. Sato et al. / Allergology International 65 (2016) 300e305 301polyposis.9 SNPs at position 954 G/C, 1173 C/T, and 1659 A/T in
the NOS2A promoter region have been shown to increase NO syn-
thesis.10 Batra et al. reported the association of NOS2A poly-
morphismwith severity of asthma and eosinophils. They also found
an association between serum nitric oxide levels and NOS2A pro-
moter repeats.11 The association between levels of FeNO and
polymorphisms in NOS2A has previously been reported. A recent
population-based study found SNPs in NOS2A to be signiﬁcantly
associatedwith FeNO, and the associationwas particularly strong in
asthmatic children.12 In a Swedish study of an adult general pop-
ulation, two SNPs in NOS2A and one in NOS3 revealed an inde-
pendent association with levels of FeNO. However, this association
varied in asthmatics, and no signiﬁcant association was found be-
tween SNPs in NOS2A and levels of FeNO.13
It should be noted that the majority of these studies were done
mainly for asthmatic patients who were already being treated with
inhaled corticosteroids, and few reports exist examining the in-
ﬂuence of polymorphisms in the NOS2A promoter region and FeNO
levels at diagnosis before the introduction of asthma treatment. For
this reason, in the present study we analyzed the proximal NOS2A
promoter pentanucleotide microsatellite and other SNPs, and
studied the association between the polymorphisms and the levels
of FeNO in asthmatics before treatment. Moreover, change in FeNO
level after asthmatic treatment was analyzed.
Methods
Study subjects and study design
Present study was a retrospective observational study. Asth-
matic subjects were recruited from the outpatient clinic at the
Department of Pulmonary Medicine in Fukushima Medical Uni-
versity Hospital between September 2009 and December 2012.
They had no abnormalities on chest X-ray and did not receive anti-
asthma therapies, including inhaled and systemic corticosteroids,
leukotriene receptor antagonists, theophylline, and omalizumab.
All patients had been diagnosed according to the American
Thoracic Society (ATS) criteria.14 Asthma was deﬁned on a basis of
recurrent episodes of at least one symptom (cough, wheeze, or
dyspnea) associated with a demonstrated reversible airﬂow limi-
tation (12% and 200 mL variability in forced expiratory volume in
1 s [FEV1] either spontaneously or with an inhaled short-acting b2-
agonist) and/or increased airway responsiveness. Asthmatics who
had upper or lower airway infection, malignancy, or collagen
vascular disease at initial assessment were excluded from the
study. Asthma severity was assessed according to the Global
Initiative of Asthma 2012 guidelines, and classiﬁed into four
groups: mild intermittent, mild persistent, moderate persistent and
severe persistent. A concomitance of chronic sinusitis was based on
the patient's report or the presence of two or more of the following
symptoms: nasal blockage/congestion, discharge, anterior/poste-
rior nasal drip, facial pain/pressure, and reduction or loss of smell.
All subjects provided written informed consent for both the anal-
ysis of their clinical data and the genotyping of their DNA extracted
from peripheral blood. If subjects were under the age of 18, they
and their guardians had to provide written informed consent prior
to enrollment. This study was approved by the ethics committee of
Fukushima Medical University on June 20, 2000 [No.65].
For initial assessment, FeNO measurement, blood tests, and
pulmonary function tests were performed, and asthma severity
was classiﬁed. All current smokers in this study stopped smoking at
least two weeks before the initial assessment. Following the initial
assessment, all recruited subjects were administered asthmatic
treatment including inhaled corticosteroids (ICS) in accordance
with treatment guidelines. During the treatment, we alsoperformed FeNO measurement for monitoring asthma control. We
deﬁned: ‘FeNO level before treatment’ as the patient's FeNO level at
diagnosis; ‘FeNO level after treatment’ as the minimum FeNO level
during the treatment periods; and ‘DFeNO’ as the difference be-
tween ‘FeNO level before treatment’ and ‘FeNO level after treat-
ment.’ According to the ATS clinical practical guidelines, ‘high FeNO
level’ in adults is deﬁned as a level higher than 50 ppb.15
FeNO measurement
FeNO was measured in accordance with ATS and European
Respiratory Society recommendations15 using a chem-
iluminescence analyzer NA623N® (Kimoto, Osaka, Japan), and is
expressed as parts per billion. NA623N® is a stationary FeNO
analyzer, and the measurement values of FeNO strongly correlated
with the valuesmeasured by awidely-used portable FeNO analyzer,
NIOX-MINO® (Aerocrine, AB, Solna, Sweden).16 Measurement was
performed as described previously.17 In brief, FeNO was measured
with patients in a sitting position andwithout the use of a nose clip.
From total lung capacity without holding their breath, the patient
exhaled at a constant ﬂow of 50 mL/s. FeNO was measured three
times, with differences in measured values within 10%. The mean
value of the three measurements was used for statistical analysis.
Blood tests and pulmonary function test
Blood tests included peripheral blood eosinophil count, serum
non-speciﬁc IgE, and antigen-speciﬁc IgE. A radioallergosorbent
test for antigen-speciﬁc IgE was performed for weeds, mites, house
dust, cats, dogs, cedar, cypress, orchard grass, moths, Aspergillus,
Candida, and mixed molds. Non-speciﬁc IgE was measured by
ﬂuorescence enzyme immunoassay (UniCAP; Pharmacia & Upjohn,
Uppsala, Sweden). Atopy was deﬁned as either a non-speciﬁc IgE
concentration greater than 250 IU/mL or any positive antigen-
speciﬁc IgE (higher than 0.70 UA/mL). Pulmonary function testing
was performed using rolling seal spirometers (Chestac-11 Cyber S-
type; Chest MI, Inc., Tokyo, Japan) to measure forced expiratory
volume (FVC) and FEV1. Tests were performed by experienced
respiratory technicians according to ATS guidelines.18 The FVC and
FEV1 are expressed as percent of predicted values.
Genotyping and analyses
Genotyping of the pentanucleotide repeats, (CCTTT)n in the
NOS2A promoter region, was performed by polymerase chain re-
action with appropriate primers (sense primer, 50-ACC CCT GGA
AGC CTA CAA CTG CAT-30; anti-sense primer, 50-GCC ACT GCA CCC
TAG CCT GTC TCA-30), and by a ﬂuorescently labeled primermethod
and capillary gel electrophoresis with an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA). Allele distri-
butionwas analyzed, and asthmatics were divided into two groups:
those with alleles with higher numbers of repeats, and all other
genotypes. Xu et al. reported on the allelic frequency of NOS2A
promoter pentanucleotide microsatellite in 210 Japanese in-
dividuals.19 In the Japanese population, alleles showed a bimodal
distribution pattern. Furthermore, previous reports on the rela-
tionship between the NOS2A promoter pentanucleotide repeat and
fatal malaria in the Gambian and Tanzanian populations deﬁned
allele length based on a trough occurring repeat number of a
bimodal distribution.20,21 We deﬁned that the cut-off number of
repeats for distinguishing lower and higher repeat was a trough
occurring repeat number of a bimodal distribution referred to these
reports. Characteristics and FeNO levels before treatment were
compared between the two groups.
Table 1
Baseline characteristics of asthmatics in separated genotype groups.
Genotype s/s Genotype L/s or L/L p value
Number (%) 67 (74) 24 (26) e
Gender (male/female) 23/44 13/11 0.088
Age (years) 54.5 ± 2.1 55.5 ± 3.1 0.813
Body mass index (kg/m2) 24.4 ± 0.6 22.8 ± 0.6 0.072
Smoking status 44/15/8 13/6/5 0.496
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2.6 kb of the NOS2A promoter in Gambians.22 We selected seven
SNPs with a population frequency of >0.05 in Gambians and UK
Caucasians from a previous report.23 We deﬁned the numbering of
SNPs on the basis of the promoter sequence published by Spitsin
et al.24 Numbering is relative to the transcriptional start site. Flu-
orogenic allele-speciﬁc TaqMan probes and primers (TaqMan SNP
Genotyping Assays, Applied Biosystems) were used for the geno-
typing of the SNPs. The primers used were as follows: (277 a/g)
rs2779248 primers; (718 a/c) rs28973255 primers; (954 g/c)
forward 50-GGG CAG ATC ACT TGA GCT TCA G-30, reverse 30-AGA
CTG GGT TTC ACC ATG TTG TC-50; (1026 g/t) forward 50-GGG AAT
ACT GTA TTT CAG GCA TTA TAA GGA-30, reverse 30-GCC TCT CAA
AGT GCT AGG ATT ACA A-50; (1173 c/t) rs9282799 primers;
(1657 c/t) rs8078340 primers; and (2441 c/g) forward 50-CAC
CTG ATC CTC CTG AGT AGC TA-30, reverse 50-CAA CAT AGT GAG ATC
CAATCT CTACAGAA-30. Allelic discriminationwas performed using
the ABI Prism 7000 Sequence Detection System (Applied
Biosystems).
Statistical analyses
All values are expressed as mean ± standard error of the mean
(SEM) unless otherwise speciﬁed. Levels of FeNO and serum total
IgE were not normally distributed and were natural log-
transformed in parametric analyses. Comparisons of patient char-
acteristics, clinical data and pulmonary function within the groups
were performed by unpaired t tests and chi-square tests, unless
otherwise speciﬁed. The correlation between levels of FeNO and
(CCTTT) pentanucleotide repeat count was performed by the
Pearson correlation coefﬁcient. The comparison between FeNO
levels before and after treatment was performed by paired t test.
Values of p < 0.05 were considered statistically signiﬁcant. Statis-
tical analysis was performed with PASW Statistics Base for Win-
dows (version 18; IBM, Armonk, NY, USA).
Results
In total, 91 asthmatics (36 males and 55 females) from the
outpatient clinic were included in the study. The mean age was 55
(range 16e78) years. All subjects with a history of childhood
asthma had outgrown their asthma in childhood. All subjects with
allergic rhinitis had not been treated with leukotriene receptor
antagonists. The numbers of asthmatics with mild intermittent,
mild persistent, moderate persistent and severe persistent severityFig. 1. Allelic distribution of NOS2A promoter microsatellite alleles in Japanese asth-
matic patients (91 subjects, 182 alleles).were 18, 40, 30, and 3, respectively. The mean FeNO level before
treatment in the 91 asthmatics was 105.1 (range 10.3e585.0) ppb.
The mean levels of FeNO before treatment in four seasons (Mar./
Apr./May, June/July/Aug., Sept./Oct./Nov., and Dec./Jan./Feb.) were
93.0 ± 18.1 ppb (n¼ 14), 104.4 ± 20.0 ppb (n¼ 22), 131.7 ± 23.4 ppb
(n ¼ 30), and 80.7 ± 13.0 ppb (n ¼ 25), respectively. No signiﬁcant
difference in FeNO levels before treatment was observed among
four seasons.
The distribution of the polymorphic (CCTTT)n repeats is shown
in Figure 1, which was substantially matched with that previously
reported in a study on the Japanese population.19 The number of
microsatellite repeats ranged from 9 to 20 and showed a bimodal
distribution, with a trough occurring at 15 repeats. We deﬁned
alleles of 14 repeats or fewer as short form (s) and alleles of 15
repeats or more as long form (L). The numbers of asthmatics in
classiﬁed genotypes were 67, 19, and 5 in genotypes s/s, L/s, and L/L,
respectively. The number of asthmatics classiﬁed as L/L genotype
was fewer than those classiﬁed as other genotypes, and there was
no signiﬁcant difference observed in mean FeNO levels before
treatment between the subjects with L/s genotype and L/L genotype
(mean ± SEM; genotype s/s 87.6 ± 9.4 ppb, L/s 162.2 ± 32.1 ppb, and
L/L 123.0 ± 43.1 ppb). The study subjects were classiﬁed into two
genotype groups: genotype L/s or L/L group (at least one allele with
a long form), and genotype s/s group (both alleles with short form).
There were no signiﬁcant differences between the two genotype
groups in the clinical characteristics and laboratory data (Table 1).
The mean FeNO level before treatment was signiﬁcantly higher in
the L/s or L/L genotype group than in the s/s genotype group
(mean ± SEM; 154.0 ± 26.8 ppb vs. 87.6 ± 9.4 ppb; p ¼ 0.019)
(Fig. 2). In addition, there was a signiﬁcant positive correlation
between FeNO level before treatment and longer (one longer allele
of two) CCTTT microsatellite repeat count (r ¼ 0.233, p ¼ 0.026)
(Fig. 3). In the comparison of clinical characteristics, no signiﬁcant
difference was observed between the L/s or L/L genotype group and
s/s genotype group regarding serum house-dust speciﬁc IgE level.
However, there was a signiﬁcant positive correlation between(never/former/current)
Allergic rhinitis (þ/) 19/48 12/12 0.055
Chronic sinusitis (þ/) 9/58 1/23 0.281
Nasal polyps (þ/) 5/62 1/23 0.577
Asthma in childhood (þ/) 5/62 3/21 0.430
Number with asthma severity
(mild intermittent/mild
persistent/moderate
persistent/severe persistent)
14/31/19/3 4/9/11/0 0.365
Blood eosinophil in WBC (%) 5.5 ± 0.5 7.0 ± 1.5 0.343
Serum total IgE (IU/mL) 220 ± 36 700 ± 260 0.254
House dustespeciﬁc IgE (þy/) 26/41 9/15 0.910
Japanese Cedarespeciﬁc IgE (þy/) 24/43 11/13 0.387
Dog or cat speciﬁc IgE (þy/) 9/58 3/21 0.908
Atopic status (%) 41 (61%) 16 (67%) 0.634
% predicted FVC (%) 94.7 ± 2.4 102.0 ± 3.7 0.119
% predicted FEV1 (%) 105.7 ± 15.7 96.8 ± 5.2 0.738
FEV1/FVC (%) 77.4 ± 1.4 75.5 ± 1.8 0.465
Data are presented as mean ± standard error of the mean unless otherwise indi-
cated.
WBC, white blood cell count; FVC, forced vital capacity; FEV1, forced expiratory
volume in 1 s; FEV1/FVC, forced expiratory volume in 1 s percent.
y Antigen speciﬁc serum IgE level is higher than 0.70 IU/mL.
Fig. 2. Comparison of FeNO levels before treatment between the two genotype groups.
The box signiﬁes the 25th and 75th percentiles, and the median is represented by a
short line within the box. The open circle indicates genotype L/s and the ﬁlled circle
indicates genotype L/L.
Fig. 3. Relationship between FeNO level and CCTTT repeat count in the NOS2A pro-
moter of longer genotype. The box signiﬁes the 25th and 75th percentiles, and the
median is represented by a short line within the box.
Table 2
Clinical characteristics and outcomes after asthmatic treatment.
Genotype s/s
(n ¼ 65)
Genotype L/s or L/L
(n ¼ 23)
p value
Treatment periods
(months)
19.5 ± 18.5 19.6 ± 20.7 0.645
Number of total FeNO
measurements (times)
4.48 ± 0.44 4.45 ± 0.41 0.290
ICS dose (equivalent
to FP) (mg/day)
583 ± 30 609 ± 48 0.660
LABA (þ/) 53/12 20/3 0.750x
LTRA (þ/) 9/56 3/20 1.000x
Theophylline (þ/) 6/59 4/19 0.281x
Highest point of
ACT score (points)
23.3 ± 0.3y 23.5 ± 0.5z 0.785
Highest % predicted
FEV1 after treatment (%)
102.5 ± 2.6 106.1 ± 2.2 0.291
FeNO level before
diagnosis (ppb)
89.6 ± 9.6 157.5 ± 27.7 0.026*
Highest FeNO level (ppb) 101.2 ± 10.8 185.1 ± 27.3 0.002*
Lowest FeNO level (ppb) 33.6 ± 3.2 41.2 ± 5.7 0.209
Data are presented as mean ± standard error of the mean unless otherwise indi-
cated.
*p < 0.05.
FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroids; FP, Fluticasone
propionate; LABA, long-acting b2-agonists; LTRA, leukotriene receptor antagonists;
ACT, asthma control test; FEV1, forced expiratory volume in 1 s.
y n ¼ 54.
z n ¼ 22.
x Comparisons were calculated with Fisher's exact test.
Table 3
Single nucleotide polymorphisms (SNPs) in proximal NOS2A promoter and FeNO
levels before treatment in asthmatics.
SNP (dbSNPy) Genotype Number (%) FeNO level (ppb) p value
277 a/g (rs2779248) a/az 77 (84.6) 104.5 ± 11.5 0.792x
a/g 12 (13.2) 108.7 ± 22.7
g/g 2 (2.2)
1026 g/t (rs2779249) g/gz 87 (95.6) 106.9 ± 10.6 0.403x
g/t 4 (4.4) 67.2 ± 33.1
t/t e
2441 c/g (rs2301369) c/cz 82 (90.1) 107.8 ± 11.1 0.576x
c/g 9 (9.9) 80.9 ± 24.6
g/g e
Four of seven analyzed SNPs (718a/c [rs28973255],954 g/c [rs1800482],1173 c/
t [rs9282799], and 1657c/t [rs8078340]) were not identiﬁed in our study subjects.
Data are presented as number(%) of subjects or mean ± standard error of mean.
NOS2A, inducible nitric oxide synthase 2A; FeNO, fractional exhaled nitric oxide.
y Reference SNP ID number of The Single Nucleotide Polymorphism Database.
z Reference genotype.
x Comparison of mean FeNO levels before treatment between subjects with
reference genotype and subjects with minor allele genotype.
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repeat count (r ¼ 0.224, p ¼ 0.034).
The FeNO levels of 88 (23 with L/s or L/L group and 65 with s/s
group) of the 91 subjects were also measured after treatment for
asthma. Table 2 shows the clinical characteristics and outcome after
asthmatic treatment. All asthmatics were treated with ICS, and no
signiﬁcant difference in the mean ICS dose between the two ge-
notype groups was observed. There were no signiﬁcant differences
in mean treatment periods (19.5 ± 18.5 months vs. 19.6 ± 20.7
months; p ¼ 0.645) and the mean number of the total FeNOmeasurements (4.48 ± 0.44 times vs. 4.45 ± 0.41 times; p ¼ 0.290)
in each subject between the two genotype groups, respectively.
After asthmatic treatment, FeNO levels were signiﬁcantly
decreased (mean ± SEM; before treatment 107.4 ± 10.5 ppb, after
treatment 35.6 ± 2.8 ppb; p < 0.001). However, the FeNO levels of
31 subjects (10 with L/s or L/L group and 21 with s/s group) were
elevated temporarily above the levels before treatment; not all
FeNO levels before treatment met the highest levels throughout the
whole period. The levels were consistently high through the whole
period also revealed a signiﬁcant positive correlation with a longer
CCTTTmicrosatellite repeat count (r¼ 0.295, p¼ 0.005). The lowest
FeNO level after treatment did not signiﬁcantly differ between the
L/s or L/L genotype group and s/s genotype group (mean ± SEM;
41.2 ± 5.7 ppb vs. 33.6 ± 3.2 ppb; p ¼ 0.209). Moreover, while no
signiﬁcant correlation between FeNO level after treatment and
longer CCTTT microsatellite repeat count was observed (r ¼ 0.155,
S. Sato et al. / Allergology International 65 (2016) 300e305304p ¼ 0.149), there was a signiﬁcant positive correlation between
DFeNO and longer (one longer allele of two) CCTTT microsatellite
repeat count (r ¼ 0.226, p ¼ 0.034). In the s/s genotype group,
signiﬁcantly fewer subjects showed ‘high FeNO levels’ (higher than
50 ppb) than in the L/s or L/L genotype group throughout the entire
period (29 of 53 [54.7%] subjects vs. 20 of 23 [87.0%] subjects;
p ¼ 0.038).
Three of seven analyzed SNPs shared by Gambians and the UK
Caucasian population were detected in the subjects, but the minor
allele frequencies were extremely low (allele frequency: 277 a/g
0.088, 1026 g/t 0.022, and 2447 c/g 0.049). Four SNPs (SNPs
[dbSNP]: 718 a/c [rs28973255], 954 g/c [rs1800482], 1173 c/t
[rs9282799], and 1657 c/t [rs8078340]) were not detected. In
single-SNP analyses, the mean FeNO levels before treatment be-
tween asthmatics with and without minor alleles were not signif-
icantly different (Table 3).
Discussion
In the current study, we analyzed the proximal NOS2A promoter
pentanucleotide microsatellite and SNPs in Japanese asthmatics.
First, the number of microsatellite repeats ranged from 9 to 20 and
showed a bimodal distribution. The mean FeNO level before
treatment was signiﬁcantly higher in longer genotype asthmatics
than in shorter genotype asthmatics. Moreover, there were signif-
icant positive correlations between FeNO levels before treatment
and longer (CCTTT) repeat length. Second, three of seven analyzed
SNPs shared with the Gambian and UK Caucasian populations were
detected in Japanese asthmatics but at lower allele frequencies.
Moreover, we analyzed the FeNO levels after asthmatic treatment
including ICS. There were no signiﬁcant differences observed in the
mean FeNO levels after treatment between the minor and major
alleles in Japanese asthmatics. The FeNO levels after treatment
including ICS were signiﬁcantly decreased. However, in the shorter
genotype group, signiﬁcantly fewer subjects showed ‘high FeNO
levels’ (higher than 50 ppb) than in the L/s or L/L genotype group
throughout the whole period as deﬁned by the ATS practical
guidelines.
There are some reports about the proximal NOS2A promoter
pentanucleotide repeat (CCTTT)n in the Japanese population. In a
study comprising 210 Japanese individuals, Xu et al. reported that
the allelic frequency of NOS2A promoter pentanucleotide repeat
(CCTTT)n showed a bimodal distribution pattern.19 Konno et al.
reported that the number of microsatellite repeats ranged from 8 to
21 in the Japanese population (141 non-atopic healthy controls, 102
atopic healthy controls, 56 non-atopic asthmatic subjects, and 198
atopic asthma subjects).8 The number of (CCTTT) pentanucleotide
repeats in their study also represented bimodal distribution. In fact,
Konno et al.'s study reported a similar number of microsatellite
repeat ranges as that in the present study, as well as a similar
distribution of allele frequency (91 Japanese asthmatics and 182
alleles).
Additionally, an association between NOS2A pentanucleotide
repeats and FeNO levels in asthmatics was reported by Leung
et al.25 Their analyses revealed that FeNO did not differ among
subjects with different NOS2A pentanucleotide repeat genotypes or
between those with none versus at least one 14-repeat allele.
However, 48% of the asthmatics in their study underwent treat-
ment with ICS before the FeNO measurement. As ICS affects FeNO
levels in asthmatics, it may have affected the results.26 In the pre-
sent study, FeNO levels were signiﬁcantly decreased after asthmatic
treatment. When we evaluated the FeNO levels of asthmatics, the
levels in asthmatics with and without anti-inﬂammatory treatment
had to be recognized as heterogeneous data. Moreover, there was a
signiﬁcant positive correlation between DFeNO and longer (onelonger allele of two) CCTTT microsatellite repeat count. From this
result, we suspect that CCTTT repeat length might affect the change
of FeNO levels in asthmatics. In the s/s genotype group, signiﬁcantly
fewer subjects revealed ‘high FeNO level’ (higher than 50 ppb) than
in the L/s or L/L genotype group throughout the entire period. Thus,
when we use the FeNO level as the control marker of asthma in
addition to a diagnostic marker, we should consider the inﬂuence of
NOS2A CCTTT repeat polymorphism.
In the sub-analysis of the present study, although a previous
report suggested that the 14-repeat allele in the NOS2A promoter
CCTTT repeat was inversely associated with atopy,8 no signiﬁcant
difference in allele distribution for the 14-repeat allele was
observed between non-atopic and atopic asthmatics (1 of 67 vs. 6 of
108; p ¼ 0.260). However, while non-atopic asthmatics did not
show a signiﬁcant correlation between CCTTT repeat count and
FeNO level before treatment, in atopic asthmatics, there was a
signiﬁcant positive correlation between longer CCTTT repeat count
and FeNO level before treatment (r ¼ 0.289, p ¼ 0.029). From this
result, we suspect that there is a possibility that FeNO levels in
atopic asthmatics are more directly inﬂuenced by NOS2A promoter
polymorphisms than FeNO levels in non-atopic asthmatics. More-
over, Pascual et al. reported a 15-repeat cut-off in nasal polyposis.9
However, in the present study, we could not detect a signiﬁcant
difference in allele distribution for the 15-repeat allele between
asthmatics with and without nasal polyps (1 of 12 alleles vs. 28 of
170 alleles; p ¼ 0.694). Few asthmatics with nasal polyps were
enrolled in this study, which may have affected the results.
While there were no signiﬁcant differences in atopic status and
serum total IgE levels between asthmatics in the s/s genotype group
and the L/s or L/L genotype group, we cannot exclude the possibility
that higher serum IgE levels affect FeNO levels in asthmatics.
However, Batra et al. reported that the CCTTT promoter repeat was
associated with serum total IgE levels in asthmatics.11 In the pre-
sent study, there was a signiﬁcant positive correlation between
serum house-dust speciﬁc IgE level and longer (CCTTT) repeat
length. Xiong et al. reported the possibility that nitric oxide mod-
ulates the Th1/Th2 balance in NOS2A knockout mice.27 They re-
ported that NOS2 deﬁciency leads to a markedly enhanced
production of IFN-g, resulting in the Th1 dominant status. On the
other hand, there is a possibility that high NOS2 activity, which
down-regulates IFN-g production, resulting in the Th2 dominant
status and enhancing IgE production. Future studies are required to
elucidate the direct relationship between NOS2A and IgE produc-
tion in asthmatics.
In the present study, we analyzed seven SNPs that included low
or no minor allele frequencies, and the minor alleles did not reveal
any signiﬁcant associations with FeNO levels before treatment in
single-SNP analyses. However, there is a possibility that the rela-
tively small sample size in the present study affected the result. The
allele frequencies of these reported SNPs in Japanese asthmatics
should be analyzed in future studies.
There are some limitations associated with our study. First, the
number of subjects was relatively fewer than those in past reports
on the relationships between iNOS promotor gene polymorphisms
and FeNO. Due to the small sample size, we could not consider
multiple logistic regression analyses or haplotype analyses of SNPs.
However, we explored the weak, yet signiﬁcant, positive correla-
tion between FeNO levels before treatment (or maximum FeNO
levels throughout the study periods) and NOS2A promoter CCTTT
microsatellite repeat count. We could follow-up on the FeNO levels
after asthmatic treatment, and evaluate the FeNO levels of asth-
matics both before and after treatment. To our knowledge, this is
the ﬁrst study to attempt such evaluation. Second, the present
study population may be atypical because of the rate of atopic
status and disease severity. In this study, the reason for the smaller
S. Sato et al. / Allergology International 65 (2016) 300e305 305ratio of the atopic subjects may be due to most subjects (91%)
having been categorized into adult onset asthma type.
In conclusion, the present study detected an association be-
tween NOS2A promoter polymorphisms and FeNO levels in Japa-
nese asthmatics before the introduction of asthmatic treatment
with ICS. To our knowledge, this is the ﬁrst report to reveal a sig-
niﬁcant association between proximal NOS2A promoter (CCTTT)
pentanucleotide microsatellite repeats and FeNO levels in asth-
matics. In Japanese asthmatics with shorter NOS2A promoter CCTTT
repeats, FeNO levels may not reﬂect the activation of eosinophilic
airway inﬂammation. In future, by applying FeNO levels as a diag-
nostic or control tool for asthma, the association of FeNO levels
with NOS2A promoter polymorphisms may provide important
diagnostic information.
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